Primecap Management Co. CA Takes $3.27 Billion Position in Biogen Inc. $BIIB

Primecap Management Co. CA acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 15,154,606 shares of the biotechnology company’s stock, valued at approximately $3,274,304,000. Biogen comprises 1.9% of Primecap Management Co. CA’s investment portfolio, making the stock its 9th biggest position. Primecap Management Co. CA owned approximately 10.26% of Biogen as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Rothschild Investment LLC raised its holdings in Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares in the last quarter. Meeder Advisory Services Inc. boosted its holdings in shares of Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after buying an additional 57 shares in the last quarter. Kera Capital Partners Inc. boosted its holdings in shares of Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 58 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after buying an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in shares of Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after buying an additional 66 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Trading Up 1.2%

Shares of Biogen stock opened at $220.77 on Wednesday. The firm’s 50 day simple moving average is $206.42 and its two-hundred day simple moving average is $195.12. The firm has a market capitalization of $32.62 billion, a price-to-earnings ratio of 39.07, a PEG ratio of 6.80 and a beta of 0.17. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $222.85. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ?4 homozygotes, could constrain uptake and increase implementation costs.

Analyst Ratings Changes

A number of research firms recently commented on BIIB. Weiss Ratings cut shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Wedbush upped their price target on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, July 30th. Bank of America lowered their price objective on Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research report on Tuesday, July 21st. Finally, Canaccord Genuity Group upped their target price on Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and an average price target of $227.79.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.